Rolling Out13h
What your pee reveals about your kidney health
Your pee reveals key insights about kidney health. Learn to read the signs in urine color, smell, and frequency to catch ...
UW Health oncologist shares signs and symptoms of kidney cancer
UW Health oncologist Dr. Nameer Mardini explains that this is a type of cancer that starts in the kidney when cells in the body grow out of control. As more cancer cells develop, they can form a tumor ...
Zacks Investment Research on MSN1d
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
Study shows tirzepatide improves biomarkers in overweight, obese adults with type 1 diabetes
In a study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for cardiovascular ...
Managed Healthcare Executive1d
FDA Approves Novartis’ Oral Fabhalta as First Treatment for C3G.
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...
BioSpace1d
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...
Fierce Pharma1d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
The American Journal of Managed Care1d
FDA Approves Oral Iptacopan for C3 Glomerulopathy
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
MedPage Today on MSN2d
First Drug Approved for Ultra-Rare Kidney Disease
The FDA approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3 glomerulopathy ...
Novartis2d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human ...